Uji Diagnostik Virus Hepatitis B dan CRISPR-Cas Sebagai Alternatif: Sebuah Tinjauan Pustaka

Authors

  • Jeanne E Christian Calvin Institute of Technology
  • Hartiyowidi Yuliawuri Program Studi Biologi, Fakultas Sains dan Teknologi, Institut Teknologi Calvin
  • Natalia Gunawan Program Studi Biologi, Fakultas Sains dan Teknologi, Institut Teknologi Calvin
  • Yolanda Charlotte Program Studi Biologi, Fakultas Sains dan Teknologi, Institut Teknologi Calvin

DOI:

https://doi.org/10.28932/jmh.v6i1.5959

Keywords:

CRISPR-Cas, cccDNA, diagnostik, VHB

Abstract

Infeksi virus hepatitis B (VHB) kronis ditandai dengan keberadaan covalently closed circular DNA (cccDNA) VHB. Metode diagnostik VHB umumnya berbasis molekuler dan serologi, tetapi metode ini memiliki kekurangan terutama di dalam mendeteksi jumlah cccDNA VHB yang rendah, mendeteksi VHB di awal tahapan infeksi, dan membedakan cccDNA dari relaxed circular DNA (rcDNA). Artikel ini bertujuan untuk membandingkan sistem diagnostik konvensional (molekular dan serologi) dengan sistem diagnostik berbasis CRISPR-Cas yang dapat menjadi alternatif uji diagnostik VHB. Metode penelitian menggunakan studi literatur mengenai diagnostik VHB secara konvensional dan metode CRISPR-Cas untuk VHB yang memenuhi kriteria inklusi dan eksklusi. Prinsip metode CRISPR dalam sistem penyuntingan genom melibatkan CRISPR-associated nuclease (Cas) dalam memodifikasi nukleotida asing yang bekerja dalam tiga tahapan yaitu adaptasi, ekspresi, dan intervensi. Beberapa penelitian penggunaan CRISPR-Cas dalam diagnostik VHB menunjukkan bahwa CRISPR-Cas dapat mendeteksi cccDNA VHB dengan sensitivitas dan spesifisitas yang tinggi. Simpulan adalah metode CRISPR-Cas dapat dikembangkan sebagai alternatif uji diagnostik infeksi VHB.

Downloads

Download data is not yet available.

References

World Health Organization. Hepatitis B. 2022 [cited 2022 Jul 28]. Available from: https://www.who.int/news-room/fact-sheets/detail/hepatitis-b.

Yano Y, Utsumi T, Lusida MI, Hayashi Y. Hepatitis B virus infection in Indonesia. World J Gastroenterol. 2015;21(38):10714–20.

Zhang X, Tian Y, Xu L, Fan Z, Cao Y, Ma Y, et al. CRISPR/Cas13-assisted hepatitis B virus covalently closed circular DNA detection. Hepatol Int. 2022;16(2):306–15.

Tsukuda S, Watashi K. Hepatitis B virus biology and life cycle. Antiviral Res. 2020;182:104925.

World Health Organization. Guidelines on Hepatitis B and C testing. 2017. p30-32, 52-59.

Centers for Diseases Control and Prevention. Viral Hepatitis. 2020 [cited 2022 Jul 28]. Available from: https://www.cdc.gov/hepatitis/populations/Born-Outside-United-States.htm.

Song JE, Kim DY. Diagnosis of hepatitis B. Ann Transl Med. 2016;4(18):338.

Kaminski MM, Abudayyeh OO, Gootenberg JS, Zhang F, Collins JJ. CRISPR-based diagnostics. Nat Biomed Eng. 2021;5(7):643–56.

Zhou K, Terrault NA. Gaps in viral hepatitis awareness in the United States in a population-based study. Clin Gastroenterol Hepatol. 2020;18(1):188-195.e4.

Kim JH, Park YK, Park E-S, Kim K-H. Molecular diagnosis and treatment of drug-resistant hepatitis B virus. World J Gastroenterol. 2014;20(19):5708–20.

Jackson K, Locarnini S, Gish R. Diagnostics of Hepatitis B Virus: Standard of Care and Investigational. Clin Liver Dis. 2018;12(1):5–11.

Haber P and Schillie S. Epidemiology and Prevention of Vaccine-Preventable Diseases: Hepatitis B. 2021 [cited 2022 Jul 30]. Available from: https://www.cdc.gov/vaccines/pubs/pinkbook/hepb.html.

Kurdi M, Abughararah M, Mulike M, Yamani O, Bugdady M, Noor M. Molecular detection of hepatitis B virus (HBV) among voluntary ELISA positive blood donors in Almadinah Almunawwarah. J Taibah Univ Med Sci. 2014;9(2):166–70.

Li X, Zhao J, QUan Q, dan Xia N. Detection of HBV Covalently Closed Circular DNA. Viruses. 2017; 9: 139.

Datta S, Chatterjee S, Veer V. Recent advances in molecular diagnostics of hepatitis B virus. World J Gastroenterol. 2014;20(40):14615–25.

Wang S, Li H, Kou Z, Ren F, Jin Y, Yang L, et al. Highly sensitive and specific detection of hepatitis B virus DNA and drug resistance mutations utilizing the PCR-based CRISPR-Cas13a system. Clin Microbiol Infect. 2021;27(3):443–50.

Zhong YW, Hu SY, Xu C, Zhao YL, Xu DP, Zhao YQ, et al. A novel method for detection of HBVcccDNA in hepatocytes using rolling circle amplification combined with in situ PCR. BMC Infect. Dis. 2014; 14: 608

Permatteo L, Scutari R, Hirichiello R, Alkhatib M, Malagnino V, Bertoli A, et al. Droplet digital PCR assay as an innovative and promising highly sensitive assay to unveil residual and cryptic HBV replication in peripheral compartment. Methods. 2022; 201:74-81.

Quoc NB, Phuong NDN, Chau NNB, Linh DTP. Closed tube loop-mediated isothermal amplification assay for rapid detection of hepatitis B virus in human blood. Heliyon. 2018;4(3):e00561. Available from: https://doi.org/10.1016/j.heliyon.2018.e00561.

Leathers JS, Pisano MB, Re V, Oord G van, Sultan A, Boonstra A, et al. Evaluation of rapid diagnostic tests for assessment of hepatitis b in resource-limited settings. Ann Glob Heal. 2019;85(1):1–3.

Wijayanti IB. Efektivitas HBsAg-Rapid Screening Test untuk Deteksi Dini Hepatitis B. Sem Schol. 2016;29–34.

Adeyemi AA, Omolade OA, Raheem-Ademola RR. Immunochromatographic Testing Method for Hepatitis B, C in Blood Donors. J Antivir Antiretrovir. 2014;S3(3):1-2.

Alhajj M, Zubair M, Farhana A. Enzyme Linked Immunosorbent Assay. StatPearls Publishing; 2023. [cited Jan 23, 2023]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK555922/#:~:text=Enzyme-linked immunosorbent assay (ELISA,proteins%2C glycoproteins%2C and hormones.

Zhang X, Tian Y, Xu L, Fan Z, Cao Y, Ma Y, et al. CRISPR/Cas13-assisted hepatitis B virus covalently closed circular DNA detection. Hepatol Int. 2022;16(2):306–15.

Hille F, Charpentier E. CRISPR-cas: Biology, mechanisms and relevance. Philos Trans R Soc B Biol Sci. 2016;371(1707):20150496.

Makarova KS, Koonin EV. Annotation and Classification of CRISPR-Cas Systems. Methods Mol Biol. 2015;1311:47–75.

Rath D, Amlinger L, Rath A, Lundgren M. The CRISPR-Cas immune system: Biology, mechanisms and applications. Biochimie. 2015;117:119–28.

Kostyusheva A, Brezgin S, Babin Y, Vasilyeva I, Glebe D, Kostyushev D, et al. CRISPR-Cas systems for diagnosing infectious diseases. Methods. 2022;203:431–46.

Makarova KS, Zhang F, Koonin E V. SnapShot: Class 2 CRISPR-Cas Systems. Cell. 2017;168(1–2):328-328.e1.

Moon SB, Kim DY, Ko J-H, Kim Y-S. Recent advances in the CRISPR genome editing tool set. Exp Mol Med. 2019;51(11):1-11.

Yuan B, Yuan C, Li L, Long M, Chen Z. Application of the CRISPR/Cas System in Pathogen Detection: A Review. Molecules. 2022; 27(20):1-15.

Jia F, Li X, Zhang C, Tang X. The expanded development and application of CRISPR system for sensitive nucleotide detection. Protein Cell. 2020;11(9):624–9.

Downloads

Published

2024-02-28

How to Cite

1.
Christian JE, Yuliawuri H, Gunawan N, Charlotte Y. Uji Diagnostik Virus Hepatitis B dan CRISPR-Cas Sebagai Alternatif: Sebuah Tinjauan Pustaka. J. Med. Health [Internet]. 2024Feb.28 [cited 2024Apr.28];6(1):103-14. Available from: https://journal.maranatha.edu/index.php/jmh/article/view/5959

Issue

Vol. 6 No. 1 (2024)

Section

Articles

License

Copyright (c) 2024 Jeanne E Christian, Hartiyowidi Yuliawuri, Natalia Gunawan, Yolanda Charlotte

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Authors who publish with this journal agree to the following terms:

  1. Authors retain the copyright and grant the journal right of first publication with the work
    simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the nonexclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.

Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.